Chemaphor Releases Business Overview Video
from Thenewswire.ca - RSS (all) by news@thenewswire.ca (TheNewswire.ca)
OTTAWA, ONTARIO, April 18, 2012 - Chemaphor has released a video summary presentation of its multi-product business development platform based on its novel OxC-beta technology. The presentation, which may be viewed at the Chemaphor website (www.chemaphor.com), is made by CEO David Hankinson who describes how the unusual combination of immune properties of OxC-beta can benefit companion animals, food-production animals and humans globally.
About OxC-beta
OxC-beta is Chemaphor's proprietary, concentrated source of oxidized carotenoid, containing oxidation compounds that occur extensively in the plant world. Results of clinical trials in animals and in vitro studies indicate OxC-beta helps support immune function, which can result in general overall health improvement.
About Chemaphor
Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.
Forward Looking Statements This news release and the video referred to above include certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained in this release or in the video referenced above that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described in the video referred to above are based on historical results. Different animals may experience different results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David Hankinson Graham Burton, PhD
CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.
Phone: 902-825-9270 Phone: 613-990-0969
d.hankinson@chemaphor.com g.burton@chemaphor.com |
